← FDA DRUG APPROVALS

FDA ANDA · ANDA209991

AMOXICILLIN AND CLAVULANATE POTASSIUM

Sponsor: DEVA HOLDING AS

APPLICATION
ANDA209991
TYPE
ANDA
ORIGINAL APPROVAL
2023-09-15
LATEST ACTION
2023-09-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AMOXICILLIN AND CLAVULANATE POTASSIUMPrescription
AMOXICILLIN 875MG, CLAVULANATE POTASSIUM EQ 125MG BASE · TABLET · ORAL

Approval history

2023-09-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →